AbbVie’s stock initially rallied on better-than-expected quarterly results, with total revenue increasing by almost 7% to over $15.4 billion. Blockbuster drugs Skyrizi and Rinvoq saw significant sales growth, while Humira declined due to biosimilar competition. Net income rose to nearly $5.3 billion, beating analyst expectations. Despite raising its 2025 guidance, AbbVie’s stock closed slightly lower after President Trump demanded lower drug prices from pharmaceutical companies, including AbbVie. Investors should note that AbbVie was not among the 10 best stocks recently identified by The Motley Fool Stock Advisor team.

Read more at Yahoo Finance: Why AbbVie Stock Slumped Today